The GLP-1 Pathway: Enhancing Incretin
Hormone Action in Patients with Type 2 Diabetes
Jerry P. Palmer, M.D.
Director, Endocrinology and Metabolism
Professor of Medicine, University of Washington
September 19, 2006
12:00-1:00 P.M.
Levin Hall 5th Floor
Watch archived presentation
(requires Internet
Explorer and Windows Media Player)
Objectives:
- Describe the role of
incretin hormones in managing glucose homeostasis;
- Explain the consequences of
diminished incretin-hormone effect in patients with type 2
diabetes;
- Discuss the potential
glucoregulatory effects of each class of agents designed to
enhance GLP-1 receptor activity;
- List the major efficacy and
safety findings from the clinical trials involving
investigational compounds that enhance GLP-1 receptor
activity.
Accreditation Statement:
The University of Texas Medical Branch at Galveston is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for
physicians. Designation Statement: The University of Texas
Medical Branch at Galveston designates this educational activity
for a maximum of 1 AMA PRA category 1 credit. Physicians
should claim only credit commensurate with the extent of their
participation in the activity.
This program (#2005-676) has also been approved by the American
Association of Critical-Care Nurses (AACN) – approved provider
(#00012890) under established AACN guidelines for 1.0 contact
hours, CERP Category A.
Methodology:
Lecture followed by question and answer session.
Disclosure Statement:
Dr. Palmer is a consultant to Amylin Pharmaceuticals, Inc. This
educational activity is financially supported by Amylin
Pharmaceuticals.
Frequent thirst
Archived Teleconference: